Skip to content
Clinical Trials – home
EstoniaBack to Estonia

Clinical trials in Nomme Linnaosa – page 8

159 clinical trials in Nomme Linnaosa, Estonia. Every trial is listed in the EU Clinical Trials Register and updated daily.

EstoniaOur site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Nomme Linnaosa at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Nomme Linnaosa

Open in trial search

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Varicella

Not recruiting

Study on the Safety of a New Chickenpox Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Study on Rosuvastatin and Atorvastatin for Preventing Heart Disease in Patients with High Genetic Risk

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Atorvastatin
  • Sponsor:University Of Tartu

Influenza

Not recruiting

Study on the Safety and Immune Response of aQIVc HD Vaccine Compared to a Drug Combination for Adults 50 Years and Older at Risk of Flu Complications

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/(H3N2)-LIKE VIRUS ANTIGEN
  • Sponsor:Seqirus UK Limited

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Estonia

The busiest research cities in the country

All 10 cities in Estonia

Clinical research in Nomme Linnaosa

What the registry says about research in the country

01 Rheumatology Research

Innovative clinical studies focusing on psoriatic arthritis treatments are evaluating long-term therapeutic solutions. The research aims to assess extended safety profiles and measure treatment effectiveness using standardized American College of Rheumatology response criteria.

  • Long-term safety assessment
  • Treatment efficacy evaluation
  • Extended patient monitoring

These trials represent significant advancement in understanding chronic inflammatory joint conditions.

02 Gastroenterology Studies

Current research initiatives are exploring new therapeutic approaches for patients with ulcerative colitis. Clinical investigations are specifically targeting moderate to severe cases, with a focus on achieving clinical remission through innovative treatment methods.

  • Clinical remission assessment
  • Inflammatory bowel disease management
  • Novel therapeutic evaluation

This research aims to expand treatment options for patients with inflammatory bowel conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.